Science Corporation's Vision-Restoring Neural Interface Receives EU Approval
Science Corporation has secured European Union approval for its vision-restoring cortical implant, a device designed to restore functional sight to individuals with certain types of blindness. The approval represents a regulatory milestone for the company, which is developing the technology as an alternative to traditional approaches in the visual prosthesis space.
The cortical implant works by directly stimulating the visual cortex—the part of the brain responsible for processing visual information. By bypassing damaged or non-functional portions of the visual pathway, the device aims to create perceived visual sensations that can help users navigate and interact with their environment.
Speaking at a recent industry event, Science Corp CEO Max Hodak emphasized the commercial viability challenges facing the field, noting that "the thing that the space needs is a company making $100 million a year of revenue." This comment highlights the broader challenge of transitioning neurotechnology from experimental research into sustainable medical products.
The EU approval allows the company to commercialize the device within European markets, potentially making the treatment available to patients who have exhausted other options for managing their visual impairment.